Document is current

Article History

Received: 24 August 2022

Accepted: 10 April 2023

First Online: 10 May 2023

Declarations

:

: Takaaki Hayashi received research funds from Alcon (Tokyo, Japan), Johnson & Johnson Vision, AMO (Tokyo, Japan), Daiichi Sankyo (Tokyo, Japan), Chugai (Tokyo, Japan), Mitsubishi Tanabe Pharma (Osaka, Japan), Senju (Osaka, Japan), Bayer (Osaka, Japan), Ritz Medical (Aichi, Japan), Uni-Hite (Kanagawa, Japan), Kuribara (Gunma, Japan), Kowa (Aichi, Japan), Kyowa Kirin (Tokyo, Japan), and Otsuka Pharma (Tokyo, Japan). The funders had no role in study design, data collection and analysis, manuscript preparation, or decision to publish.

: The study protocol was approved by the Institutional Review Board of the Jikei University School of Medicine (approval no. 24–231 6997). The protocol adhered to the tenets of the Declaration of Helsinki.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: This article does not contain any studies with animals performed by any of the authors.

: Written informed consent was obtained from the patient for publication of this case report.